FDA Drug Approval Summary: Lapatinib in Combination with Capecitabine for Previously Treated Metastatic Breast Cancer That

Lapatinib:clinical benefit in patients with HER2-positive advanced breast cancer

Kroep, J. R.
Linn, S. C.
Boven, E.
Bloemendal, H. J.
Baas, J.
Mandjes, I. A. M.
Smit, W. M.
de Graaf, H.
Schroder, C. P.
Vermeulen, G. J.
Hop, W. C. J.
Nortier, J. W. R.

September 2010

Background: Lapatinib, a tyrosine kinase inhibitor of human epidermal growth factor receptor 2 (HER2...

Lapatinib:clinical benefit in patients with HER2-positive advanced breast cancer

Kroep, J. R.
Linn, S. C.
Boven, E.
Bloemendal, H. J.
Baas, J.
Mandjes, I. A. M.
Smit, W. M.
de Graaf, H.
Schroder, C. P.
Vermeulen, G. J.
Hop, W. C. J.
Nortier, J. W. R.

September 2010

Background: Lapatinib, a tyrosine kinase inhibitor of human epidermal growth factor receptor 2 (HER2...

Lapatinib: clinical benefit in patients with HER2-positive advanced breast cancer

Kroep, J.R.
Linn, S.C.
, E. boven
Bloemendal, H.J.
Baas, J.
Mandjes, I.A.M.
Bosch, J. van den
Smit, W.M.
Graaf, H. de
Schroder, C.P.
Vermeulen, G.J.
Hop, W.C.J.
Nortier, J.W.R.

September 2010

Background: Lapatinib, a tyrosine kinase inhibitor of human epidermal growth factor receptor 2 (HER2...

FDA Drug Approval Summary: Lapatinib in Combination with Capecitabine for Previously Treated Metastatic Breast Cancer That

Robert Justice
Richard Pazdur
Qin Ryan
Amna Ibrahim
Martin H. Cohen
John Johnson
Chia-wen Ko
Overexpresses Her
Qin Ryan
Amna Ibrahim
Martin H. Cohen
John Johnson
Chia-wen Ko
Rajeshwari Sridhara
Robert Justice
Richard Pazdur

January 1634

located on the World Wide Web at: The online version of this article, along with updated information...

FDA Drug Approval Summary: Lapatinib in Combination with Capecitabine for Previously Treated Metastatic Breast Cancer That

Robert Justice
Richard Pazdur
Qin Ryan
Amna Ibrahim
Martin H. Cohen
John Johnson
Chia-wen Ko
Overexpresses Her
Qin Ryan
Amna Ibrahim
Martin H. Cohen
John Johnson
Chia-wen Ko
Rajeshwari Sridhara
Robert Justice
Richard Pazdur

February 2015

located on the World Wide Web at: The online version of this article, along with updated information...

FDA Drug Approval Summary: Alemtuzumab as Single-Agent Treatment for B-Cell Chronic Lymphocytic Leukemia

Suzanne Demko
Jeffrey Summers
Patricia Keegan
Richard Pazdur
Suzanne Demko
Jeffrey Summers
Patricia Keegan
Richard Pazdur

January 2015

located on the World Wide Web at: The online version of this article, along with updated information...

Capecitabine in Combination with Novel Targeted Agents in the Management of Metastatic Breast Cancer: Underlying Rationale and Results of Clinical Trials

Debu Tripathy
Debu Tripathy

January 2015

located on the World Wide Web at: The online version of this article, along with updated information...

FDA Drug Approval Summary: Pemetrexed for Injection (Alimta®) for the Treatment of Non-Small Cell Lung Cancer

Richard Pazdur
Martin H. Cohen
John R. Johnson
Yong-cheng Wang
Rajeshwari Sridhara
Martin H. Cohen
John R. Johnson
Yong-cheng Wang
Rajeshwari Sridhara
Richard Pazdur

January 2004

located on the World Wide Web at: The online version of this article, along with updated information...

FDA Drug Approval Summary: Pemetrexed for Injection (Alimta®) for the Treatment of Non-Small Cell Lung Cancer

Richard Pazdur
Martin H. Cohen
John R. Johnson
Yong-cheng Wang
Rajeshwari Sridhara
Martin H. Cohen
John R. Johnson
Yong-cheng Wang
Rajeshwari Sridhara
Richard Pazdur

January 2004

located on the World Wide Web at: The online version of this article, along with updated information...

Single-Agent Capecitabine: A Reference Treatment for Taxane-Pretreated Metastatic Breast Cancer?

Andrew D. Seidman
Jean-louis Misset
Andrew D. Seidman
A Joyce O’shaughnessy
B Jean-louis Missetc

February 2015

located on the World Wide Web at: The online version of this article, along with updated information...

Single-Agent Capecitabine: A Reference Treatment for Taxane-Pretreated Metastatic Breast Cancer?

Andrew D. Seidman
Jean-louis Misset
Andrew D. Seidman
A Joyce O’shaughnessy
B Jean-louis Missetc

February 2015

located on the World Wide Web at: The online version of this article, along with updated information...

The Role of Capecitabine in First-Line Treatment for Patients with Metastatic Breast Cancer

Karen Gelmon
Arlene Chan
Nadia Harbeck
Karen Gelmon
A Arlene Chan
B Nadia Harbeckc

January 2006

located on the World Wide Web at: The online version of this article, along with updated information...

The Role of Capecitabine in First-Line Treatment for Patients with Metastatic Breast Cancer

Karen Gelmon
Arlene Chan
Nadia Harbeck
Karen Gelmon
A Arlene Chan
B Nadia Harbeckc

January 2006

located on the World Wide Web at: The online version of this article, along with updated information...

Lapatinib:clinical benefit in patients with HER2-positive advanced breast cancer

Kroep, J. R.
Linn, S. C.
Boven, E.
Bloemendal, H. J.
Baas, J.
Mandjes, I. A. M.
Smit, W. M.
de Graaf, H.
Schroder, C. P.
Vermeulen, G. J.
Hop, W. C. J.
Nortier, J. W. R.

September 2010

Background: Lapatinib, a tyrosine kinase inhibitor of human epidermal growth factor receptor 2 (HER2...

R.; FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma. Oncologist

Martin H. Cohen
John R. Johnson
Robert Justice
Richard Pazdur
Martin H. Cohen
John R. Johnson
Robert Justice
Richard Pazdur

February 2015

located on the World Wide Web at: The online version of this article, along with updated information...

Lapatinib:clinical benefit in patients with HER2-positive advanced breast cancer

Kroep, J. R.
Linn, S. C.
Boven, E.
Bloemendal, H. J.
Baas, J.
Mandjes, I. A. M.
Smit, W. M.
de Graaf, H.
Schroder, C. P.
Vermeulen, G. J.
Hop, W. C. J.
Nortier, J. W. R.

September 2010

Background: Lapatinib, a tyrosine kinase inhibitor of human epidermal growth factor receptor 2 (HER2...

Lapatinib:clinical benefit in patients with HER2-positive advanced breast cancer

Kroep, J. R.
Linn, S. C.
Boven, E.
Bloemendal, H. J.
Baas, J.
Mandjes, I. A. M.
Smit, W. M.
de Graaf, H.
Schroder, C. P.
Vermeulen, G. J.
Hop, W. C. J.
Nortier, J. W. R.

September 2010

Background: Lapatinib, a tyrosine kinase inhibitor of human epidermal growth factor receptor 2 (HER2...

Lapatinib: clinical benefit in patients with HER2-positive advanced breast cancer

Kroep, J.R.
Linn, S.C.
, E. boven
Bloemendal, H.J.
Baas, J.
Mandjes, I.A.M.
Bosch, J. van den
Smit, W.M.
Graaf, H. de
Schroder, C.P.
Vermeulen, G.J.
Hop, W.C.J.
Nortier, J.W.R.

September 2010

Background: Lapatinib, a tyrosine kinase inhibitor of human epidermal growth factor receptor 2 (HER2...

FDA Drug Approval Summary: Lapatinib in Combination with Capecitabine for Previously Treated Metastatic Breast Cancer That

Robert Justice
Richard Pazdur
Qin Ryan
Amna Ibrahim
Martin H. Cohen
John Johnson
Chia-wen Ko
Overexpresses Her
Qin Ryan
Amna Ibrahim
Martin H. Cohen
John Johnson
Chia-wen Ko
Rajeshwari Sridhara
Robert Justice
Richard Pazdur

January 1634

located on the World Wide Web at: The online version of this article, along with updated information...

FDA Drug Approval Summary: Lapatinib in Combination with Capecitabine for Previously Treated Metastatic Breast Cancer That

Robert Justice
Richard Pazdur
Qin Ryan
Amna Ibrahim
Martin H. Cohen
John Johnson
Chia-wen Ko
Overexpresses Her
Qin Ryan
Amna Ibrahim
Martin H. Cohen
John Johnson
Chia-wen Ko
Rajeshwari Sridhara
Robert Justice
Richard Pazdur

February 2015

located on the World Wide Web at: The online version of this article, along with updated information...

FDA Drug Approval Summary: Alemtuzumab as Single-Agent Treatment for B-Cell Chronic Lymphocytic Leukemia

Suzanne Demko
Jeffrey Summers
Patricia Keegan
Richard Pazdur
Suzanne Demko
Jeffrey Summers
Patricia Keegan
Richard Pazdur

January 2015

located on the World Wide Web at: The online version of this article, along with updated information...

Capecitabine in Combination with Novel Targeted Agents in the Management of Metastatic Breast Cancer: Underlying Rationale and Results of Clinical Trials

Debu Tripathy
Debu Tripathy

January 2015

located on the World Wide Web at: The online version of this article, along with updated information...

FDA Drug Approval Summary: Pemetrexed for Injection (Alimta®) for the Treatment of Non-Small Cell Lung Cancer

Richard Pazdur
Martin H. Cohen
John R. Johnson
Yong-cheng Wang
Rajeshwari Sridhara
Martin H. Cohen
John R. Johnson
Yong-cheng Wang
Rajeshwari Sridhara
Richard Pazdur

January 2004

located on the World Wide Web at: The online version of this article, along with updated information...

FDA Drug Approval Summary: Pemetrexed for Injection (Alimta®) for the Treatment of Non-Small Cell Lung Cancer

Richard Pazdur
Martin H. Cohen
John R. Johnson
Yong-cheng Wang
Rajeshwari Sridhara
Martin H. Cohen
John R. Johnson
Yong-cheng Wang
Rajeshwari Sridhara
Richard Pazdur

January 2004

located on the World Wide Web at: The online version of this article, along with updated information...

Single-Agent Capecitabine: A Reference Treatment for Taxane-Pretreated Metastatic Breast Cancer?

Andrew D. Seidman
Jean-louis Misset
Andrew D. Seidman
A Joyce O’shaughnessy
B Jean-louis Missetc

February 2015

located on the World Wide Web at: The online version of this article, along with updated information...

Single-Agent Capecitabine: A Reference Treatment for Taxane-Pretreated Metastatic Breast Cancer?

Andrew D. Seidman
Jean-louis Misset
Andrew D. Seidman
A Joyce O’shaughnessy
B Jean-louis Missetc

February 2015

located on the World Wide Web at: The online version of this article, along with updated information...

The Role of Capecitabine in First-Line Treatment for Patients with Metastatic Breast Cancer

Karen Gelmon
Arlene Chan
Nadia Harbeck
Karen Gelmon
A Arlene Chan
B Nadia Harbeckc

January 2006

located on the World Wide Web at: The online version of this article, along with updated information...

The Role of Capecitabine in First-Line Treatment for Patients with Metastatic Breast Cancer

Karen Gelmon
Arlene Chan
Nadia Harbeck
Karen Gelmon
A Arlene Chan
B Nadia Harbeckc

January 2006

located on the World Wide Web at: The online version of this article, along with updated information...

Lapatinib:clinical benefit in patients with HER2-positive advanced breast cancer

Kroep, J. R.
Linn, S. C.
Boven, E.
Bloemendal, H. J.
Baas, J.
Mandjes, I. A. M.
Smit, W. M.
de Graaf, H.
Schroder, C. P.
Vermeulen, G. J.
Hop, W. C. J.
Nortier, J. W. R.

September 2010

Background: Lapatinib, a tyrosine kinase inhibitor of human epidermal growth factor receptor 2 (HER2...

R.; FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma. Oncologist

Martin H. Cohen
John R. Johnson
Robert Justice
Richard Pazdur
Martin H. Cohen
John R. Johnson
Robert Justice
Richard Pazdur

February 2015

located on the World Wide Web at: The online version of this article, along with updated information...

Lapatinib:clinical benefit in patients with HER2-positive advanced breast cancer

Kroep, J. R.
Linn, S. C.
Boven, E.
Bloemendal, H. J.
Baas, J.
Mandjes, I. A. M.
Smit, W. M.
de Graaf, H.
Schroder, C. P.
Vermeulen, G. J.
Hop, W. C. J.
Nortier, J. W. R.

September 2010

Background: Lapatinib, a tyrosine kinase inhibitor of human epidermal growth factor receptor 2 (HER2...

Lapatinib:clinical benefit in patients with HER2-positive advanced breast cancer

Kroep, J. R.
Linn, S. C.
Boven, E.
Bloemendal, H. J.
Baas, J.
Mandjes, I. A. M.
Smit, W. M.
de Graaf, H.
Schroder, C. P.
Vermeulen, G. J.
Hop, W. C. J.
Nortier, J. W. R.

September 2010

Background: Lapatinib, a tyrosine kinase inhibitor of human epidermal growth factor receptor 2 (HER2...

Lapatinib: clinical benefit in patients with HER2-positive advanced breast cancer

Kroep, J.R.
Linn, S.C.
, E. boven
Bloemendal, H.J.
Baas, J.
Mandjes, I.A.M.
Bosch, J. van den
Smit, W.M.
Graaf, H. de
Schroder, C.P.
Vermeulen, G.J.
Hop, W.C.J.
Nortier, J.W.R.

September 2010

Background: Lapatinib, a tyrosine kinase inhibitor of human epidermal growth factor receptor 2 (HER2...

FDA Drug Approval Summary: Lapatinib in Combination with Capecitabine for Previously Treated Metastatic Breast Cancer That

Abstract

Extracted data

FDA Drug Approval Summary: Lapatinib in Combination with Capecitabine for Previously Treated Metastatic Breast Cancer That

Abstract

Extracted data

Related items

Related items